134 related articles for article (PubMed ID: 1551909)
41. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
Brower MS; Harpel PC
J Biol Chem; 1982 Aug; 257(16):9849-54. PubMed ID: 6980881
[TBL] [Abstract][Full Text] [Related]
42. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1.
Chesne S; Villiers CL; Arlaud GJ; Lacroix MB; Colomb MG
Biochem J; 1982 Jan; 201(1):61-70. PubMed ID: 6282262
[TBL] [Abstract][Full Text] [Related]
43. Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation.
Aulak KS; Pemberton PA; Rosen FS; Carrell RW; Lachmann PJ; Harrison RA
Biochem J; 1988 Jul; 253(2):615-8. PubMed ID: 3178731
[TBL] [Abstract][Full Text] [Related]
44. C1 inhibitor and hereditary angioneurotic edema.
Davis AE
Annu Rev Immunol; 1988; 6():595-628. PubMed ID: 3289579
[No Abstract] [Full Text] [Related]
45. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
de Agostini A; Patston PA; Marottoli V; Carrel S; Harpel PC; Schapira M
J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
[TBL] [Abstract][Full Text] [Related]
46. Inactivation of kallikrein in human plasma.
van der Graaf F; Koedam JA; Bouma BN
J Clin Invest; 1983 Jan; 71(1):149-58. PubMed ID: 6184384
[TBL] [Abstract][Full Text] [Related]
47. Primary structure of the reactive site of human C1-inhibitor.
Salvesen GS; Catanese JJ; Kress LF; Travis J
J Biol Chem; 1985 Feb; 260(4):2432-6. PubMed ID: 3919001
[TBL] [Abstract][Full Text] [Related]
48. Functional analysis of the serpin domain of C1 inhibitor.
Coutinho M; Aulak KS; Davis AE
J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
[TBL] [Abstract][Full Text] [Related]
49. Structural and circular-dichroism studies on the interaction between human C1-esterase inhibitor and C1s.
Nilsson T; Sjöholm I; Wiman B
Biochem J; 1983 Sep; 213(3):617-24. PubMed ID: 6604523
[TBL] [Abstract][Full Text] [Related]
50. Effect of reactive site loop elongation on the inhibitory activity of C1-inhibitor.
Bos IG; Lubbers YT; Eldering E; Abrahams JP; Hack CE
Biochim Biophys Acta; 2004 Jun; 1699(1-2):139-44. PubMed ID: 15158721
[TBL] [Abstract][Full Text] [Related]
51. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.
Sherman PM; Lawrence DA; Yang AY; Vandenberg ET; Paielli D; Olson ST; Shore JD; Ginsburg D
J Biol Chem; 1992 Apr; 267(11):7588-95. PubMed ID: 1559996
[TBL] [Abstract][Full Text] [Related]
52. C1-inhibitor-serine proteinase complexes and the biosynthesis of C1-inhibitor by Hep G2 and U 937 cells.
Patston PA; Medcalf RL; Kourteva Y; Schapira M
Blood; 1993 Dec; 82(11):3371-9. PubMed ID: 8241507
[TBL] [Abstract][Full Text] [Related]
53. Antibody-independent interaction between the first component of human complement, C1, and the outer membrane of Escherichia coli D31 m4.
Aubert B; Chesne S; Arlaud GJ; Colomb MG
Biochem J; 1985 Dec; 232(2):513-9. PubMed ID: 3911948
[TBL] [Abstract][Full Text] [Related]
54. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen.
Schapira M; Scott CF; Colman RW
Biochemistry; 1981 May; 20(10):2738-43. PubMed ID: 6910423
[TBL] [Abstract][Full Text] [Related]
55. Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.
Parad RB; Kramer J; Strunk RC; Rosen FS; Davis AE
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6786-90. PubMed ID: 2118657
[TBL] [Abstract][Full Text] [Related]
56. A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor.
Bianchino AC; Poon PH; Schumaker VN
J Immunol; 1988 Dec; 141(11):3930-6. PubMed ID: 3183385
[TBL] [Abstract][Full Text] [Related]
57. The inhibition of TNK-t-PA by C1-inhibitor.
Sulikowski T; Patston PA
Blood Coagul Fibrinolysis; 2001 Jan; 12(1):75-7. PubMed ID: 11229830
[TBL] [Abstract][Full Text] [Related]
58. Biological activities of C1 inhibitor.
Davis AE; Mejia P; Lu F
Mol Immunol; 2008 Oct; 45(16):4057-63. PubMed ID: 18674818
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of subtilisin BPN' by reaction site P1 mutants of Streptomyces subtilisin inhibitor.
Kojima S; Nishiyama Y; Kumagai I; Miura K
J Biochem; 1991 Mar; 109(3):377-82. PubMed ID: 1908859
[TBL] [Abstract][Full Text] [Related]
60. In vitro interaction of C1-inhibitor with thrombin.
Cugno M; Bos I; Lubbers Y; Hack CE; Agostoni A
Blood Coagul Fibrinolysis; 2001 Jun; 12(4):253-60. PubMed ID: 11460008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
